BIOCRYST PHARMACEUTICALS INC - Common Stock (BCRX)
CUSIP: 09058V103
Q2 2022 13F Holders as of 30 Jun 2022
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 210,587,372
- Total 13F shares
- 151,882,406
- Share change
- +24,412,917
- Total reported value
- $1,606,941,793
- Put/Call ratio
- 81%
- Price per share
- $10.58
- Number of holders
- 207
- Value change
- +$202,016,904
- Number of buys
- 104
- Number of sells
- 103
Quarterly Holders Quick Answers
What is CUSIP 09058V103?
CUSIP 09058V103 identifies BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 09058V103:
Top shareholders of BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock Finance, Inc. |
13F
|
Company |
6.7%
|
14,101,975
|
$229,298,000 | — | 31 Mar 2022 | |
| VANGUARD GROUP INC |
13F
|
Company |
6.3%
|
13,207,040
|
$214,746,000 | — | 31 Mar 2022 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
6%
|
12,710,818
|
$206,678,000 | — | 31 Mar 2022 | |
| FMR LLC |
13F
|
Company |
4%
|
8,414,458
|
$136,819,000 | — | 31 Mar 2022 | |
| STATE STREET CORP |
13F
|
Company |
3.5%
|
7,462,752
|
$121,344,000 | — | 31 Mar 2022 | |
| PICTET ASSET MANAGEMENT SA |
13F
|
Company |
2.4%
|
5,106,903
|
$83,038,000 | — | 31 Mar 2022 | |
| Fisher Asset Management, LLC |
13F
|
Company |
1.9%
|
3,986,823
|
$64,826,000 | — | 31 Mar 2022 | |
| RP Management, LLC |
13F
|
Company |
1.8%
|
3,846,154
|
$62,538,000 | — | 31 Mar 2022 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
1.7%
|
3,553,521
|
$57,538,000 | — | 31 Mar 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.6%
|
3,281,978
|
$53,364,000 | — | 31 Mar 2022 | |
| Artisan Partners Limited Partnership |
13F
|
Company |
1.3%
|
2,841,405
|
$46,201,000 | — | 31 Mar 2022 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
1.2%
|
2,457,215
|
$38,775,000 | — | 31 Mar 2022 | |
| LOOMIS SAYLES & CO L P |
13F
|
Company |
1.1%
|
2,356,216
|
$38,312,000 | — | 31 Mar 2022 | |
| LORD, ABBETT & CO. LLC |
13F
|
Company |
1.1%
|
2,318,016
|
$37,691,000 | — | 31 Mar 2022 | |
| Avoro Capital Advisors LLC |
13F
|
Company |
0.89%
|
1,875,000
|
$30,488,000 | — | 31 Mar 2022 | |
| STIFEL FINANCIAL CORP |
13F
|
Company |
0.88%
|
1,850,342
|
$30,086,000 | — | 31 Mar 2022 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.85%
|
1,799,898
|
$29,266,000 | — | 31 Mar 2022 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.84%
|
1,771,012
|
$28,797,000 | — | 31 Mar 2022 | |
| ORACLE INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.82%
|
1,720,733
|
$27,979,000 | — | 31 Mar 2022 | |
| BNP Paribas Asset Management Holding S.A. |
13F
|
Company |
0.79%
|
1,665,256
|
$27,077,000 | — | 31 Mar 2022 | |
| Sarissa Capital Management LP |
13F
|
Company |
0.66%
|
1,390,790
|
$22,614,000 | — | 31 Mar 2022 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.64%
|
1,346,841
|
$21,900,000 | — | 31 Mar 2022 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.6%
|
1,273,625
|
$20,709,000 | — | 31 Mar 2022 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.59%
|
1,239,751
|
$20,158,000 | — | 31 Mar 2022 | |
| ALKEON CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.56%
|
1,187,845
|
$19,314,000 | — | 31 Mar 2022 | |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC |
13F
|
Company |
0.03%
|
57,000
|
$19,282,000 | — | 31 Mar 2022 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.52%
|
1,085,846
|
$17,656,000 | — | 31 Mar 2022 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
0.48%
|
1,012,000
|
$16,455,000 | — | 31 Mar 2022 | |
| SEGALL BRYANT & HAMILL, LLC |
13F
|
Company |
0.45%
|
943,792
|
$15,346,000 | — | 31 Mar 2022 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.42%
|
892,108
|
$14,506,000 | — | 31 Mar 2022 | |
| NORGES BANK |
13F
|
Company |
0.38%
|
795,528
|
$12,935,285 | — | 31 Mar 2022 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.35%
|
736,414
|
$11,974,000 | — | 31 Mar 2022 | |
| MORGAN STANLEY |
13F
|
Company |
0.34%
|
710,047
|
$11,545,000 | — | 31 Mar 2022 | |
| Lisanti Capital Growth, LLC |
13F
|
Company |
0.31%
|
662,644
|
$10,775,000 | — | 31 Mar 2022 | |
| MPM BioImpact LLC |
13F
|
Company |
0.3%
|
639,089
|
$10,392,000 | — | 31 Mar 2022 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.27%
|
574,249
|
$9,338,000 | — | 31 Mar 2022 | |
| Bain Capital Public Equity Management II, LLC |
13F
|
Company |
0.25%
|
520,199
|
$8,458,000 | — | 31 Mar 2022 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.25%
|
519,050
|
$8,440,000 | — | 31 Mar 2022 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.23%
|
476,978
|
$7,756,000 | — | 31 Mar 2022 | |
| Granahan Investment Management, LLC |
13F
|
Company |
0.22%
|
469,430
|
$7,633,000 | — | 31 Mar 2022 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.21%
|
449,156
|
$7,303,000 | — | 31 Mar 2022 | |
| North Star Investment Management Corp. |
13F
|
Company |
0.21%
|
443,400
|
$7,210,000 | — | 31 Mar 2022 | |
| Swiss National Bank |
13F
|
Company |
0.2%
|
425,468
|
$6,918,000 | — | 31 Mar 2022 | |
| NEW YORK STATE COMMON RETIREMENT FUND |
13F
|
Company |
0.19%
|
403,195
|
$6,556,000 | — | 31 Mar 2022 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.19%
|
392,008
|
$6,374,000 | — | 31 Mar 2022 | |
| Ghost Tree Capital, LLC |
13F
|
Company |
0.17%
|
350,000
|
$5,691,000 | — | 31 Mar 2022 | |
| GILDER GAGNON HOWE & CO LLC |
13F
|
Company |
0.16%
|
339,009
|
$5,512,000 | — | 31 Mar 2022 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
0.16%
|
331,713
|
$5,394,000 | — | 31 Mar 2022 | |
| Allianz Asset Management GmbH |
13F
|
Company |
0.14%
|
305,179
|
$4,962,000 | — | 31 Mar 2022 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.14%
|
303,008
|
$4,927,000 | — | 31 Mar 2022 |
Institutional Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock (BCRX) as of Q2 2022
As of 30 Jun 2022,
BIOCRYST PHARMACEUTICALS INC - Common Stock (BCRX) was held by
207 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
151,882,406 shares.
The largest 10 holders included
BlackRock Inc., VANGUARD GROUP INC, BAKER BROS. ADVISORS LP, STATE STREET CORP, Avoro Capital Advisors LLC, PICTET ASSET MANAGEMENT SA, Fisher Asset Management, LLC, FMR LLC, VICTORY CAPITAL MANAGEMENT INC, and MORGAN STANLEY.
This page lists
207
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2022 vs Q1 2022 Across Filers
Q1 2022 holders
219
Q2 2022 holders
207
Holder diff
-12
| Investor | Q1 2022 Shares | Q2 2022 Shares | Share Diff | Share Chg % | Q1 2022 Value $ | Q2 2022 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.